Inovio Pharmaceuticals, Inc. (INO)
1.67
-0.02
(-1.18%)
USD |
NASDAQ |
Nov 19, 12:59
Inovio Pharmaceuticals Max Drawdown (5Y) : 99.62% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 99.62% |
| September 30, 2026 | 99.62% |
| August 31, 2026 | 99.62% |
| July 31, 2026 | 99.62% |
| June 30, 2026 | 99.62% |
| May 31, 2026 | 99.62% |
| April 30, 2026 | 99.62% |
| March 31, 2026 | 99.62% |
| February 28, 2026 | 99.62% |
| January 31, 2026 | 99.62% |
| December 31, 2025 | 99.62% |
| November 30, 2025 | 99.62% |
| October 31, 2025 | 99.62% |
| September 30, 2025 | 99.62% |
| August 31, 2025 | 99.62% |
| July 31, 2025 | 99.62% |
| June 30, 2025 | 99.62% |
| May 31, 2025 | 99.62% |
| April 30, 2025 | 99.62% |
| March 31, 2025 | 99.57% |
| February 28, 2025 | 99.53% |
| January 31, 2025 | 99.53% |
| December 31, 2024 | 99.53% |
| November 30, 2024 | 98.96% |
| October 31, 2024 | 98.90% |
| Date | Value |
|---|---|
| September 30, 2024 | 98.90% |
| August 31, 2024 | 98.90% |
| July 31, 2024 | 98.90% |
| June 30, 2024 | 98.90% |
| May 31, 2024 | 98.90% |
| April 30, 2024 | 98.90% |
| March 31, 2024 | 98.90% |
| February 29, 2024 | 98.90% |
| January 31, 2024 | 98.90% |
| December 31, 2023 | 98.90% |
| November 30, 2023 | 98.90% |
| October 31, 2023 | 98.87% |
| September 30, 2023 | 98.82% |
| August 31, 2023 | 98.78% |
| July 31, 2023 | 98.78% |
| June 30, 2023 | 98.78% |
| May 31, 2023 | 98.14% |
| April 30, 2023 | 97.80% |
| March 31, 2023 | 97.50% |
| February 28, 2023 | 96.09% |
| January 31, 2023 | 95.55% |
| December 31, 2022 | 95.55% |
| November 30, 2022 | 95.46% |
| October 31, 2022 | 95.46% |
| September 30, 2022 | 95.46% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Precigen, Inc. | 95.58% |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Ionis Pharmaceuticals, Inc. | 70.27% |
| Nektar Therapeutics | 99.39% |
| Rigel Pharmaceuticals, Inc. | 86.40% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -80.78 |
| Beta (5Y) | 1.709 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 93.27% |
| Historical Sharpe Ratio (5Y) | -0.7157 |
| Historical Sortino (5Y) | -1.641 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 36.79% |